Apr 83 min read

Recent Biopharma Funding Activity - April 8th

Check out the following recent activity in the biopharma funding space. Take a closer look at 43 notable updates for this week:

Want to get this list of recently funded companies and more data? Fill out a quote request to get more info or set up a call (Quote Request Form)

– Private Funding –

Surrozen

💸 Entered into a $192.5M private placement to fund the SZN-043 clinical development program.

Obsidian Therapeutics

💸 Raised $160.5M Series C financing led Wellington Management and will go towards enrolling more patients for its OBX-115 drug trial for NSCLC.

ImmPACT Bio USA Inc.

💸 $141.7M offering w/ $139.8M already sold.

Alterome Therapeutics

💸 Raised $132M in Series B financing led by Goldman Sachs Alternatives to advance the development of the AKT1 E17K & KRAS selective inhibitor candidates.

Diagonal Therapeutics

💸 Launched w/ $128M in financing to pioneer a new approach to discovering and developing agonist antibodies.

ImmunoGenesis, Inc.

💸 $66.5M offering w/ $44.4M already sold.

Neurosterix

💸 Launched w/ $63M funding to advance allosteric modulator therapeutics (e.g., M4 PAM) for neurological disorders.

Biolinq

💸 Raised $58M in funding led by Alpha Wave Ventures to support the completion pivotal trial this year, proprietary intradermal glucose sensor evaluation, and subsequent FDA submission.

Selux Diagnostics

💸 Raised an additional $48M in funding to launch their next phase of commercialization of the Selux Next Generation Phenotyping (NGP) system within the US.

Protara Therapeutics

💸 Entered into an oversubscribed $45M private placement financing to fund the company into 2026.

EnteroBiotix

💸 Completed £27M ($34M) funding round supported by various investors to advance EBX-102-02 through a Ph2 trial treating IBS and also to other drug pipelines.

Melt Pharmaceuticals

💸 Closed $24M Series B funding from various investors to further the development of MELT-300.

Biofidelity

💸 Raised $24M financing to accelerate commercialization of ASPYRE®-Lung novel test for NSCLC in the US.

Miach Orthopaedics

💸 Raised $20M in Series B extension funding to support commercial expansion and clinical activities for the BEAR implant for anterior cruciate ligament (ACL) tears.

iBio, Inc.

💸 $15M equity financing

Delphinus Medical Technologies, Inc.

💸 $15M debt financing w/ $5.2M already sold.

Delova Biotech

💸 Completed >100M CNY ($14M) in Series B+ financing led by several investors

UniXell Biotechnology

💸 Completed >100M CNY ($14M) in Series A financing led by Tasly Capital to accelerate the clinical research pipeline and support the industrialization of innovative cell therapy drugs.

Conformation-X Therapeutics

💸 Secured $13.5M in funding to advance its immune-oncology pipeline.

AI Proteins, Inc.

💸 $10M debt financing w/ $4.9M already sold.

Carmell Corp.

💸 Announces $3M private placement.

Mach5 Therapeutics, Inc.

💸 $2.9M offering w/ $2.6M already sold.

Mercury Bio, Inc.

💸 $2M offering w/ $149.9K already sold.

Juniper Biomedical

💸 Secured $2M Series Seed funding led by Auroral Holdings and $1M through the NIH SPARC Neuromod prize to accelerate development in the pelvic health disorders space.

Precision Epigenomics Inc

💸 $1.7M offering w/ $1.1M already sold.

Anchor Balloon, Inc.

💸 $1.5M debt financing.

BetterLife

💸 Closed $1.168M convertible debentures to further advance IND-enabling studies of its non-hallucinogenic LSD-based candidate, BETR-001.

Medibiofarma

💸 Closed €1M ($1M) financing round to further the clinical phase of MBF-118, MBF-015, and MBF-362.

Ironic Biotech

💸 Raised €1M ($1M) led by Nordic Foodtech VC to develop interventions for both iron deficiency and anemia.

Cessation Therapeutics

💸 $1M offering.

Addiction Cure Therapeutic Sciences Inc

💸 $1M offering.

Bio-Path Holdings, Inc.

💸 $317K warranted option.

Gemina Laboratories Ltd.

💸 $302K debt financing.

Sirona Biochem

💸 Closed CAD 132K ($97K) of private placement to be used for general working capital.

Swan NeuroTech, Inc.

💸 $95K debt financing

– Post-IPO/Public Funding –

Rhythm Pharmaceuticals

💸 Sold $150M in Series A convertible preferred stock in a financing led by Perceptive Advisors, LLC. The financing extends its cash runway into 2026, enabling a topline data readout from its Ph3 trial in hypothalamic obesity in H1 2025.

Gritstone bio

🏦 $32M public offering.

Sutro Biopharma

🏦 $7M underwritten offering.

BioLineRx

🏦 $6M registered direct offering.

Biora Therapeutics